Pfizer (PFE) announced the proposed acquisition of Metsera (MTSR) for $47.50 per share in cash at closing and a $22.50 CVR, BTIG tells investors in a research note. The firm views this deal, which follows Roche’s (RHHBY) acquisition of 89bio (ETNB) as providing a positive readthrough to Viking (VKTX). BTIG, which reiterates a Buy rating and $125 price target, sees the deal sharpening Viking’s clinical updates and strategic optionality, bolstering sentiment ahead of key clinical readouts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
- Viking Therapeutics Stock Plummets: What’s Behind the Drop?
- Largest borrow rate increases among liquid names
- Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho
- Unusually active option classes on open August 20th